{"parse":{"title":"Isosorbide dinitrate/hydralazine","pageid":3694563,"revid":847826784,"text":{"*":"<div class=\"mw-parser-output\"><table class=\"infobox\" style=\"width:22em;border-spacing:2px;\"><caption><span title=\"International nonproprietary name (INN): Isosorbide dinitrate/hydralazine\">Isosorbide dinitrate/hydralazine</span></caption><tbody><tr><th colspan=\"2\" style=\"text-align:center;background:#ddd\">Combination of</th></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/Isosorbide_dinitrate\" title=\"Isosorbide dinitrate\">Isosorbide dinitrate</a></th><td>\n<a href=\"/wiki/Vasodilator\" class=\"mw-redirect\" title=\"Vasodilator\">Vasodilator</a></td></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/Hydralazine\" title=\"Hydralazine\">Hydralazine</a></th><td>\n<a href=\"/wiki/Antihypertensive\" class=\"mw-redirect\" title=\"Antihypertensive\">Antihypertensive</a></td></tr><tr><th colspan=\"2\" style=\"text-align:center;background:#ddd\">Identifiers</th></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/CAS_Registry_Number\" title=\"CAS Registry Number\">CAS Number</a></th><td>\n<div class=\"plainlist\"><ul><li><span title=\"www.commonchemistry.org\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.commonchemistry.org/ChemicalDetail.aspx?ref=682335-44-0\">682335-44-0</a></span><sup>&#160;<img alt=\"\u2612\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png\" width=\"7\" height=\"8\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/11px-X_mark.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/14px-X_mark.svg.png 2x\" data-file-width=\"525\" data-file-height=\"600\" /><span style=\"display:none\">N</span></sup></li></ul></div></td></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/PubChem#CID\" title=\"PubChem\">PubChem</a> <span style=\"font-weight:normal\"><abbr title=\"Compound ID\">CID</abbr></span></th><td>\n<div class=\"plainlist\"><ul><li><span title=\"pubchem.ncbi.nlm.nih.gov\"><a rel=\"nofollow\" class=\"external text\" href=\"https://pubchem.ncbi.nlm.nih.gov/compound/9843669\">9843669</a></span></li></ul></div></td></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/ChemSpider\" title=\"ChemSpider\">ChemSpider</a></th><td>\n<div class=\"plainlist\"><ul><li><span title=\"www.chemspider.com\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.chemspider.com/Chemical-Structure.8019384.html\">8019384</a></span><sup>&#160;<img alt=\"\u2611\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png\" width=\"7\" height=\"7\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x\" data-file-width=\"600\" data-file-height=\"600\" /><span style=\"display:none\">Y</span></sup></li></ul></div></td></tr><tr><th scope=\"row\" style=\"padding:0.2em 0; line-height:1.2em;\"><a href=\"/wiki/KEGG\" title=\"KEGG\">KEGG</a></th><td>\n<div class=\"plainlist\"><ul><li><span title=\"www.kegg.jp\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.kegg.jp/entry/D10209\">D10209</a></span><sup>&#160;<img alt=\"\u2612\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png\" width=\"7\" height=\"8\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/11px-X_mark.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/14px-X_mark.svg.png 2x\" data-file-width=\"525\" data-file-height=\"600\" /><span style=\"display:none\">N</span></sup></li></ul></div></td></tr><tr><th colspan=\"2\" style=\"text-align:center;background:#ddd\"><span style=\"font-weight:normal;\">&#160;<sup><img alt=\"\u2612\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png\" width=\"7\" height=\"8\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/11px-X_mark.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/14px-X_mark.svg.png 2x\" data-file-width=\"525\" data-file-height=\"600\" /><span style=\"display:none\">N</span><img alt=\"\u2611\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png\" width=\"7\" height=\"7\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x\" data-file-width=\"600\" data-file-height=\"600\" /><span style=\"display:none\">Y</span></sup>&#160;<a href=\"/wiki/Wikipedia:WikiProject_Chemicals/Chembox_validation\" title=\"Wikipedia:WikiProject Chemicals/Chembox validation\">(what is this?)</a></span><span style=\"font-weight:normal;\">&#160;&#160;<span class=\"reflink plainlinks nourlexpansion\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Special:ComparePages&amp;rev1=470456386&amp;page2=Isosorbide+dinitrate%2Fhydralazine\">(verify)</a></span></span></th></tr></tbody></table>\n<table class=\"plainlinks metadata ambox ambox-content ambox-globalize\" role=\"presentation\"><tbody><tr><td class=\"mbox-image\"><div style=\"width:52px\"><img alt=\"Globe icon.\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/bd/Ambox_globe_content.svg/48px-Ambox_globe_content.svg.png\" width=\"48\" height=\"40\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/bd/Ambox_globe_content.svg/73px-Ambox_globe_content.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/bd/Ambox_globe_content.svg/97px-Ambox_globe_content.svg.png 2x\" data-file-width=\"350\" data-file-height=\"290\" /></div></td><td class=\"mbox-text\"><div class=\"mbox-text-span\">The examples and perspective in this article <b>may not represent a <a href=\"/wiki/Wikipedia:WikiProject_Countering_systemic_bias\" title=\"Wikipedia:WikiProject Countering systemic bias\">worldwide view</a> of the subject</b>.<span class=\"hide-when-compact\"> You may <a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Isosorbide_dinitrate/hydralazine&amp;action=edit\">improve this article</a>, discuss the issue on the <a href=\"/wiki/Talk:Isosorbide_dinitrate/hydralazine\" title=\"Talk:Isosorbide dinitrate/hydralazine\">talk page</a>, or <a href=\"/wiki/Wikipedia:Article_wizard\" title=\"Wikipedia:Article wizard\">create a new article</a>, as appropriate.</span>  <small><i>(May 2016)</i></small><small class=\"hide-when-compact\"><i> (<a href=\"/wiki/Help:Maintenance_template_removal\" title=\"Help:Maintenance template removal\">Learn how and when to remove this template message</a>)</i></small></div></td></tr></tbody></table>\n<p><b>Isosorbide dinitrate/hydralazine</b> is a fixed dose combination drug treatment specifically approved by the US FDA to be used to treat <a href=\"/wiki/African_Americans\" title=\"African Americans\">African Americans</a> with <a href=\"/wiki/Congestive_heart_failure\" class=\"mw-redirect\" title=\"Congestive heart failure\">congestive heart failure</a>.  It is a combination of <a href=\"/wiki/Hydralazine\" title=\"Hydralazine\">hydralazine</a> (an <a href=\"/wiki/Antihypertensive\" class=\"mw-redirect\" title=\"Antihypertensive\">antihypertensive</a>) and <a href=\"/wiki/Isosorbide_dinitrate\" title=\"Isosorbide dinitrate\">isosorbide dinitrate</a> (a <a href=\"/wiki/Vasodilator\" class=\"mw-redirect\" title=\"Vasodilator\">vasodilator</a>).<sup id=\"cite_ref-Ferdinand2014rev_1-0\" class=\"reference\"><a href=\"#cite_note-Ferdinand2014rev-1\">&#91;1&#93;</a></sup>  It is the first <a href=\"/wiki/Race_(classification_of_human_beings)\" class=\"mw-redirect\" title=\"Race (classification of human beings)\">race</a>-based <a href=\"/wiki/Prescription_drug\" title=\"Prescription drug\">prescription drug</a> in the <a href=\"/wiki/United_States\" title=\"United States\">United States</a>.<sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup><sup class=\"reference\" style=\"white-space:nowrap;\">:<span>7</span></sup>\n</p><p>The combination preparation is marketed in the United States under the trade name <b>BiDil</b> by <a href=\"/w/index.php?title=Arbor_Pharmaceuticals,_Inc.&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Arbor Pharmaceuticals, Inc. (page does not exist)\">Arbor Pharmaceuticals, Inc.</a> which purchased the rights to market the drug in December 2011 from NitroMed.\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Background\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Background</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Controversy\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Controversy</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#See_also\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#References\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#External_links\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">External links</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Background\">Background</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Isosorbide_dinitrate/hydralazine&amp;action=edit&amp;section=1\" title=\"Edit section: Background\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>From 1980 to 1985 Dr. Jay Cohn of the University of Minnesota led a clinical trial in collaboration with the US <a href=\"/wiki/Veterans_Administration\" class=\"mw-redirect\" title=\"Veterans Administration\">Veterans Administration</a> called the Vasodilator-Heart Failure Trial (V-HeFT I) that tested whether the combination of  Isosorbide dinitrate and hydralazine increased survival in patients with heart failure; the results were promising and the study was followed by V-HeFT II, which tested the combination against <a href=\"/wiki/Enalapril\" title=\"Enalapril\">enalapril</a>.<sup id=\"cite_ref-Kahn_3-0\" class=\"reference\"><a href=\"#cite_note-Kahn-3\">&#91;3&#93;</a></sup>  In the meantime, Cohn applied for a patent on the combination treatment, which issued in 1989 as US Patent 4868179.<sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup>  Cohn licensed the patent to a company called Medco, and Medco spent the early 1990s preparing a <a href=\"/wiki/New_Drug_Application\" title=\"New Drug Application\">New Drug Application</a> (NDA) to get the FDA to approve BiDil on the basis of the V-HeFT trials. However, the trials were not designed to support an NDA, and in 1997 the FDA rejected the application because it did not have enough <a href=\"/wiki/Statistical_power\" class=\"mw-redirect\" title=\"Statistical power\">statistical power</a> to show whether the combination really worked.<sup id=\"cite_ref-Kahn_3-1\" class=\"reference\"><a href=\"#cite_note-Kahn-3\">&#91;3&#93;</a></sup>\n</p><p>Cohn re-analyzed the data and found a signal that the drug combination appeared to work better in self-identified African-Americans in the V-HeFT trial, and published a paper on that work, and filed a new patent on the use of BiDil in \"black\" patients.<sup id=\"cite_ref-Kahn_3-2\" class=\"reference\"><a href=\"#cite_note-Kahn-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup><sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup>   It had already been known that African-Americans with congestive heart failure (CHF) respond less effectively to conventional CHF treatments (particularly <a href=\"/wiki/ACE_inhibitor\" title=\"ACE inhibitor\">ACE inhibitors</a>) than caucasians.<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup>\n</p><p>The new patent and the old patent were licensed to a company called NitroMed, which ran a clinical called the African-American Heart Failure Trial (A-HeFT), the results of which were published in 2004 in the New England Journal of Medicine.<sup id=\"cite_ref-Taylor_8-0\" class=\"reference\"><a href=\"#cite_note-Taylor-8\">&#91;8&#93;</a></sup>  The clinical trial was stopped early because the drug worked so well; it reduced mortality by 43%, reduced hospitalizations by 39%, and improved quality of life markers in African-American patients with CHF.<sup id=\"cite_ref-Taylor_8-1\" class=\"reference\"><a href=\"#cite_note-Taylor-8\">&#91;8&#93;</a></sup>\n</p><p>On the basis of A-HeFT, the FDA approved BiDil in June 2005.<sup id=\"cite_ref-Kahn_3-3\" class=\"reference\"><a href=\"#cite_note-Kahn-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup><sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup>  In 2006, the Heart Failure Society of America included the use of the fixed dose combination of isosorbide dinitrate/hydralazine as the standard of care in the treatment of heart failure in blacks.<sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup><sup class=\"reference\" style=\"white-space:nowrap;\">:<span>e44</span></sup>\n</p><p>Though BiDil must still be taken three times daily, as must the component pills in separate ISDN-H treatment, the reduction in pill burden has been suggested to improve compliance, and thus a better medical outcome.<sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Controversy\">Controversy</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Isosorbide_dinitrate/hydralazine&amp;action=edit&amp;section=2\" title=\"Edit section: Controversy\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The new drug application claiming treatment of a single, self-identified racial group raised a storm of controversy. Some hailed the development of BiDil as a breakthrough for African Americans (such groups included the Black congressional Caucus, the Association of Black Cardiologists, the National Medical Association, and the National Association for the Advancement of Colored People) and a step to addressing the unique health care needs and <a href=\"/wiki/Race_and_health_in_the_United_States#African-Americans\" title=\"Race and health in the United States\">health disparities of the African American community</a>.<sup id=\"cite_ref-Roberts_13-0\" class=\"reference\"><a href=\"#cite_note-Roberts-13\">&#91;13&#93;</a></sup>\n</p><p>Others who criticized the preliminary studies argued that the original study did not have a significant number of African-American subjects to make the BiDil's race specific claims,<sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup> and that the results of only one clinical trial where African-Americans were tested does not provide a full and comprehensive study.<sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup> Furthermore, critics argued that self-identified racial identifications from patients as an indicator for race during the trials were not a sufficient categorization method because these self-identifications were socially constructed and have no biological connection to genomic data.<sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup>\n</p><p>They argued that the trials represented a new form of scientific racism where race, a socially constructed category, would continue to be present in research as a placeholder for genomic identification.<sup id=\"cite_ref-Kahn_3-4\" class=\"reference\"><a href=\"#cite_note-Kahn-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-17\" class=\"reference\"><a href=\"#cite_note-17\">&#91;17&#93;</a></sup><sup id=\"cite_ref-18\" class=\"reference\"><a href=\"#cite_note-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-19\" class=\"reference\"><a href=\"#cite_note-19\">&#91;19&#93;</a></sup><sup id=\"cite_ref-20\" class=\"reference\"><a href=\"#cite_note-20\">&#91;20&#93;</a></sup><sup id=\"cite_ref-21\" class=\"reference\"><a href=\"#cite_note-21\">&#91;21&#93;</a></sup>\n</p><p>Additionally, some disagreed with the design of the A-HeFT trial because the trial failed to include any non-African American test subjects.<sup id=\"cite_ref-Puckrein2006_22-0\" class=\"reference\"><a href=\"#cite_note-Puckrein2006-22\">&#91;22&#93;</a></sup> The trial was designed to include only African American test subjects, therefore failing to show that BiDil has a greater effectiveness in African Americans than those in other races.<sup id=\"cite_ref-23\" class=\"reference\"><a href=\"#cite_note-23\">&#91;23&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Isosorbide_dinitrate/hydralazine&amp;action=edit&amp;section=3\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/Pharmacogenetics\" title=\"Pharmacogenetics\">Pharmacogenetics</a></li>\n<li><a href=\"/wiki/Pharmacogenomics\" title=\"Pharmacogenomics\">Pharmacogenomics</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Isosorbide_dinitrate/hydralazine&amp;action=edit&amp;section=4\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-Ferdinand2014rev-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Ferdinand2014rev_1-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Ferdinand, KC; Elkayam, U; Mancini, D; Ofili, E; Pi\u00f1a, I; Anand, I; Feldman, AM; McNamara, D; Leggett, C (1 July 2014). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.ajconline.org/article/S0002-9149(14)00975-8/pdf\">\"Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial\"</a>. <i>The American Journal of Cardiology</i>. <b>114</b> (1): 151\u20139. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.amjcard.2014.04.018\">10.1016/j.amjcard.2014.04.018</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/24846808\">24846808</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+American+Journal+of+Cardiology&amp;rft.atitle=Use+of+isosorbide+dinitrate+and+hydralazine+in+African-Americans+with+heart+failure+9+years+after+the+African-American+Heart+Failure+Trial.&amp;rft.volume=114&amp;rft.issue=1&amp;rft.pages=151-9&amp;rft.date=2014-07-01&amp;rft_id=info%3Adoi%2F10.1016%2Fj.amjcard.2014.04.018&amp;rft_id=info%3Apmid%2F24846808&amp;rft.aulast=Ferdinand&amp;rft.aufirst=KC&amp;rft.au=Elkayam%2C+U&amp;rft.au=Mancini%2C+D&amp;rft.au=Ofili%2C+E&amp;rft.au=Pi%C3%B1a%2C+I&amp;rft.au=Anand%2C+I&amp;rft.au=Feldman%2C+AM&amp;rft.au=McNamara%2C+D&amp;rft.au=Leggett%2C+C&amp;rft_id=http%3A%2F%2Fwww.ajconline.org%2Farticle%2FS0002-9149%2814%2900975-8%2Fpdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AIsosorbide+dinitrate%2Fhydralazine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation book\">Whitmarsh, Ian; Jones, David S., eds. (2010). <a rel=\"nofollow\" class=\"external text\" href=\"http://mitpress.mit.edu/sites/default/files/titles/content/9780262514248_sch_0001.pdf\"><i>What's the Use of Race?: Modern Governance and the Biology of Difference</i></a> <span style=\"font-size:85%;\">(PDF)</span>. Cambridge (MA): MIT Press. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-262-51424-8\" title=\"Special:BookSources/978-0-262-51424-8\">978-0-262-51424-8</a>. <a rel=\"nofollow\" class=\"external text\" href=\"http://www.bionews.org.uk/page_111448.asp\">Lay summary</a> (28 April 2013).</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=What%27s+the+Use+of+Race%3F%3A+Modern+Governance+and+the+Biology+of+Difference&amp;rft.place=Cambridge+%28MA%29&amp;rft.pub=MIT+Press&amp;rft.date=2010&amp;rft.isbn=978-0-262-51424-8&amp;rft_id=http%3A%2F%2Fmitpress.mit.edu%2Fsites%2Fdefault%2Ffiles%2Ftitles%2Fcontent%2F9780262514248_sch_0001.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AIsosorbide+dinitrate%2Fhydralazine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Kahn-3\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Kahn_3-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Kahn_3-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Kahn_3-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Kahn_3-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Kahn_3-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\">Jonathan Kahn.  BiDil and Racialized Medicine.  Chapter 7 in <a rel=\"nofollow\" class=\"external text\" href=\"https://books.google.com/books?id=OVg4AAAAQBAJ\">Race and the Genetic Revolution: Science, Myth, and Culture</a>, Eds Sheldon Krimsky and Kathleen Sloan. Columbia University Press. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-231-52769-9\" title=\"Special:BookSources/978-0-231-52769-9\">978-0-231-52769-9</a></span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.google.com/patents/US4868179\">US4868179</a></span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\">Carson P, et al. <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pubmed/10496190\">Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group</a> J Card Fail. 1999 Sep;5(3):178-87.</span>\n</li>\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.google.com/patents/US6465463\">US Patent 6465463</a></span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Exner DV, Dries DL, Domanski MJ, Cohn JN (2001). \"Lesser response to angiotensin-converting-enzyme inhibitor therapy in blacks as compared with white patients with left ventricular dysfunction\". <i><a href=\"/wiki/N_Engl_J_Med\" class=\"mw-redirect\" title=\"N Engl J Med\">N Engl J Med</a></i>. <b>344</b> (18): 1351\u20137. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/NEJM200105033441802\">10.1056/NEJM200105033441802</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/11333991\">11333991</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N+Engl+J+Med&amp;rft.atitle=Lesser+response+to+angiotensin-converting-enzyme+inhibitor+therapy+in+blacks+as+compared+with+white+patients+with+left+ventricular+dysfunction&amp;rft.volume=344&amp;rft.issue=18&amp;rft.pages=1351-7&amp;rft.date=2001&amp;rft_id=info%3Adoi%2F10.1056%2FNEJM200105033441802&amp;rft_id=info%3Apmid%2F11333991&amp;rft.aulast=Exner&amp;rft.aufirst=DV&amp;rft.au=Dries%2C+DL&amp;rft.au=Domanski%2C+MJ&amp;rft.au=Cohn%2C+JN&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AIsosorbide+dinitrate%2Fhydralazine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Taylor-8\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Taylor_8-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Taylor_8-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN (2004). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.nejm.org/doi/full/10.1056/NEJMoa042934#t=article\">\"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure\"</a>. <i>N Engl J Med</i>. <b>351</b> (20): 2049\u201357. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/NEJMoa042934\">10.1056/NEJMoa042934</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/15533851\">15533851</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N+Engl+J+Med&amp;rft.atitle=Combination+of+isosorbide+dinitrate+and+hydralazine+in+blacks+with+heart+failure&amp;rft.volume=351&amp;rft.issue=20&amp;rft.pages=2049-57&amp;rft.date=2004&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMoa042934&amp;rft_id=info%3Apmid%2F15533851&amp;rft.aulast=Taylor&amp;rft.aufirst=AL&amp;rft.au=Ziesche%2C+S&amp;rft.au=Yancy%2C+C&amp;rft.au=Carson%2C+P&amp;rft.au=D%27Agostino+R+Jr&amp;rft.au=Ferdinand%2C+K&amp;rft.au=Taylor%2C+M&amp;rft.au=Adams%2C+K&amp;rft.au=Sabolinski%2C+M&amp;rft.au=Worcel%2C+M&amp;rft.au=Cohn%2C+JN&amp;rft_id=http%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa042934%23t%3Darticle&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AIsosorbide+dinitrate%2Fhydralazine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&amp;DrugName=BIDIL\">FDA approval process page</a></span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/bbs/topics/NEWS/2005/NEW01190.html\">FDA approval press release</a></span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\">Heart Failure Society of America. <a rel=\"nofollow\" class=\"external text\" href=\"http://www.ancecardio.it/it/doc/1160866289744_hfsa_2006_comprehensive_heart_failure_guidelines.pdf\">HFSA 2006 Comprehensive Heart Failure Practice Guideline</a> <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20110728080810/http://www.ancecardio.it/it/doc/1160866289744_hfsa_2006_comprehensive_heart_failure_guidelines.pdf\">Archived</a> 2011-07-28 at the <a href=\"/wiki/Wayback_Machine\" title=\"Wayback Machine\">Wayback Machine</a>. \nJ Card Fail. 2006 Feb;12(1):e1-e122.</span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\"><cite id=\"CITEREFSteve_Stiles2006\" class=\"citation\">Steve Stiles (13 December 2006), <a rel=\"nofollow\" class=\"external text\" href=\"http://www.theheart.org/article/759547/print.do\"><i>BiDil, regulatory milestone but a tough sell for insurers and patients, charts uncertain course</i></a></cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=BiDil%2C+regulatory+milestone+but+a+tough+sell+for+insurers+and+patients%2C+charts+uncertain+course&amp;rft.date=2006-12-13&amp;rft.au=Steve+Stiles&amp;rft_id=http%3A%2F%2Fwww.theheart.org%2Farticle%2F759547%2Fprint.do&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AIsosorbide+dinitrate%2Fhydralazine\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Roberts-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Roberts_13-0\">^</a></b></span> <span class=\"reference-text\">Dorothy Roberts.  The Color Coded Pill.  Chapter 8 in <a rel=\"nofollow\" class=\"external text\" href=\"https://books.google.com/books/about/Fatal_Invention.html?id=_TsaXOpTCSYC\">Fatal Invention: How Science, Politics, and Big Business Re-create Race in the Twenty-first Century</a>. The New Press. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-1-595-58834-0\" title=\"Special:BookSources/978-1-595-58834-0\">978-1-595-58834-0</a></span>\n</li>\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\">Roberts 2011, p. 171</span>\n</li>\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\">Roberts 2011, p. 174</span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\">Roberts 2011, p. 175</span>\n</li>\n<li id=\"cite_note-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-17\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.wnyc.org/shows/radiolab/episodes/2008/11/28/segments/113776\">WNYC <i>Radiolab</i> audio story about racial issues surrounding Bidil</a></span>\n</li>\n<li id=\"cite_note-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-18\">^</a></b></span> <span class=\"reference-text\">Editors, Scientific American. July 31, 2007 <a rel=\"nofollow\" class=\"external text\" href=\"http://www.scientificamerican.com/article.cfm?id=race-based-medicine-a-recipe-for-controversy\">Race-Based Medicine: A Recipe for Controversy</a></span>\n</li>\n<li id=\"cite_note-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-19\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.sciam.com/article.cfm?id=race-in-a-bottle\"><i>Scientific American</i> article criticizing approval of Bidil</a></span>\n</li>\n<li id=\"cite_note-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-20\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.sciam.com/article.cfm?articleID=194ECC1C-E7F2-99DF-3A3D043D92095CD6\"><i>Scientific American</i> article response by manufacturer to previous article's criticism</a></span>\n</li>\n<li id=\"cite_note-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-21\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fdaweb.com/login.php?sa=v&amp;aid=D5106490&amp;cate=&amp;stid=%241%24L44.2y1.%24rb7LwxobMB2m145JqeU6V\">Response for FDA's Robert Temple to <i>Scientific American</i> article</a></span>\n</li>\n<li id=\"cite_note-Puckrein2006-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Puckrein2006_22-0\">^</a></b></span> <span class=\"reference-text\">Puckrein, G. (2006). BiDil: From Another Vantage Point. Health Affairs . Retrieved October 1, 2013, from <a rel=\"nofollow\" class=\"external free\" href=\"http://content.healthaffairs.org/content/25/5/w368.long\">http://content.healthaffairs.org/content/25/5/w368.long</a></span>\n</li>\n<li id=\"cite_note-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-23\">^</a></b></span> <span class=\"reference-text\">Margaret Kimberly, AlterNet. June 27, 2005 <a rel=\"nofollow\" class=\"external text\" href=\"http://www.alternet.org/story/23185/a_bitter_pill_for_black_hearts\">A Bitter Pill for Black Hearts</a></span>\n</li>\n</ol></div>\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Isosorbide_dinitrate/hydralazine&amp;action=edit&amp;section=5\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.bidil.com/\">Official website</a></li></ul>\n\n<!-- \nNewPP limit report\nParsed by mw1327\nCached time: 20180909114026\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.432 seconds\nReal time usage: 0.530 seconds\nPreprocessor visited node count: 4618/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 39693/2097152 bytes\nTemplate argument size: 3609/2097152 bytes\nHighest expansion depth: 16/40\nExpensive parser function count: 2/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 16494/5000000 bytes\nNumber of Wikibase entities loaded: 1/400\nLua time usage: 0.145/10.000 seconds\nLua memory usage: 3.66 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  469.526      1 -total\n 61.91%  290.668      1 Template:Drugbox\n 41.37%  194.257      1 Template:Infobox\n 27.49%  129.083      1 Template:Reflist\n 14.57%   68.404     15 Template:Unbulleted_list\n 10.89%   51.150      3 Template:Cite_journal\n  6.68%   31.373      2 Template:ISBN\n  6.63%   31.112      1 Template:Globalize\n  6.34%   29.783      1 Template:Infobox_drug/chemical_formula\n  5.37%   25.194      1 Template:Ambox\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:3694563-0!canonical and timestamp 20180909114026 and revision id 847826784\n -->\n</div>"},"langlinks":[{"lang":"sr","url":"https://sr.wikipedia.org/wiki/Izosorbid_dinitrat/hidralazin","langname":"Serbian","autonym":"\u0441\u0440\u043f\u0441\u043a\u0438 / srpski","*":"Izosorbid dinitrat/hidralazin"},{"lang":"sh","url":"https://sh.wikipedia.org/wiki/Izosorbid_dinitrat/hidralazin","langname":"Serbo-Croatian","autonym":"srpskohrvatski / \u0441\u0440\u043f\u0441\u043a\u043e\u0445\u0440\u0432\u0430\u0442\u0441\u043a\u0438","*":"Izosorbid dinitrat/hidralazin"}],"categories":[{"sortkey":"","hidden":"","*":"Webarchive_template_wayback_links"},{"sortkey":"Isosorbide dinitrate hydralazine","hidden":"","*":"Articles_with_changed_CASNo_identifier"},{"sortkey":"Isosorbide dinitrate hydralazine","hidden":"","*":"Articles_with_changed_KEGG_identifier"},{"sortkey":"*","hidden":"","*":"Articles_without_EBI_source"},{"sortkey":"*","hidden":"","*":"Chemical_pages_without_DrugBank_identifier"},{"sortkey":"*","hidden":"","*":"Articles_without_InChI_source"},{"sortkey":"*","hidden":"","*":"Articles_without_UNII_source"},{"sortkey":"Isosorbide dinitrate hydralazine","hidden":"","*":"Drugs_missing_an_ATC_code"},{"sortkey":"Isosorbide dinitrate hydralazine","hidden":"","*":"Drugs_with_no_legal_status"},{"sortkey":"Isosorbide dinitrate hydralazine","hidden":"","*":"Drugboxes_which_contain_changes_to_verified_fields"},{"sortkey":"Isosorbide dinitrate hydralazine","hidden":"","*":"Drugboxes_which_contain_changes_to_watched_fields"},{"sortkey":"2","hidden":"","*":"Drugs_that_are_a_combination_of_chemicals"},{"sortkey":"Isosorbide dinitrate hydralazine","hidden":"","*":"Articles_with_limited_geographic_scope_from_May_2016"},{"sortkey":"Isosorbide dinitrate hydralazine","*":"Antihypertensive_agents"},{"sortkey":"Isosorbide dinitrate hydralazine","*":"Vasodilators"},{"sortkey":"Isosorbide dinitrate hydralazine","*":"Combination_drugs"},{"sortkey":"Isosorbide dinitrate hydralazine","*":"Race_and_health"}],"links":[{"ns":0,"*":"Isosorbide dinitrate/hydralazine (data page)"},{"ns":0,"exists":"","*":"ACE inhibitor"},{"ns":0,"exists":"","*":"African Americans"},{"ns":0,"exists":"","*":"Antihypertensive"},{"ns":0,"exists":"","*":"CAS Registry Number"},{"ns":0,"exists":"","*":"ChemSpider"},{"ns":0,"exists":"","*":"Congestive heart failure"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Enalapril"},{"ns":0,"exists":"","*":"Hydralazine"},{"ns":0,"exists":"","*":"International Standard Book Number"},{"ns":0,"exists":"","*":"Isosorbide dinitrate"},{"ns":0,"exists":"","*":"KEGG"},{"ns":0,"exists":"","*":"N Engl J Med"},{"ns":0,"exists":"","*":"New Drug Application"},{"ns":0,"exists":"","*":"Pharmacogenetics"},{"ns":0,"exists":"","*":"Pharmacogenomics"},{"ns":0,"exists":"","*":"Prescription drug"},{"ns":0,"exists":"","*":"PubChem"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Race (classification of human beings)"},{"ns":0,"exists":"","*":"Race and health in the United States"},{"ns":0,"exists":"","*":"Statistical power"},{"ns":0,"exists":"","*":"United States"},{"ns":0,"exists":"","*":"Vasodilator"},{"ns":0,"exists":"","*":"Veterans Administration"},{"ns":0,"exists":"","*":"Wayback Machine"},{"ns":0,"*":"Arbor Pharmaceuticals, Inc."},{"ns":14,"exists":"","*":"Category:Articles with limited geographic scope from May 2016"},{"ns":1,"exists":"","*":"Talk:Isosorbide dinitrate/hydralazine"},{"ns":4,"exists":"","*":"Wikipedia:Article wizard"},{"ns":4,"exists":"","*":"Wikipedia:WikiProject Chemicals/Chembox validation"},{"ns":4,"exists":"","*":"Wikipedia:WikiProject Countering systemic bias"},{"ns":12,"exists":"","*":"Help:Maintenance template removal"}],"templates":[{"ns":10,"exists":"","*":"Template:Drugbox"},{"ns":10,"exists":"","*":"Template:Infobox drug"},{"ns":10,"exists":"","*":"Template:Infobox"},{"ns":10,"exists":"","*":"Template:Infobox drug/title"},{"ns":10,"exists":"","*":"Template:Both"},{"ns":10,"exists":"","*":"Template:Infobox drug/licence"},{"ns":10,"exists":"","*":"Template:Infobox drug/pregnancy category"},{"ns":10,"exists":"","*":"Template:Unbulleted list"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatATC"},{"ns":10,"exists":"","*":"Template:Infobox drug/legal status"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatCASnumber"},{"ns":10,"exists":"","*":"Template:Cascite"},{"ns":10,"exists":"","*":"Template:Cross"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatPubChemCID"},{"ns":10,"exists":"","*":"Template:Abbr"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatPubChemSID"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatIUPHARBPS"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatDrugBank"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatChemSpider"},{"ns":10,"exists":"","*":"Template:Chemspidercite"},{"ns":10,"exists":"","*":"Template:Tick"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatUNII"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatKEGG"},{"ns":10,"exists":"","*":"Template:Keggcite"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatChEBI"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatChEMBL"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatChemDBNIAID"},{"ns":10,"exists":"","*":"Template:Infobox drug/chemical formula"},{"ns":10,"exists":"","*":"Template:Chembox Elements/molecular formula"},{"ns":10,"exists":"","*":"Template:Chem molar mass"},{"ns":10,"exists":"","*":"Template:Chem molar mass/format"},{"ns":10,"exists":"","*":"Template:Yesno"},{"ns":10,"exists":"","*":"Template:Infobox drug/formatJmol"},{"ns":10,"exists":"","*":"Template:Nobold"},{"ns":10,"exists":"","*":"Template:Template other"},{"ns":10,"exists":"","*":"Template:Button"},{"ns":10,"exists":"","*":"Template:Border-radius"},{"ns":10,"exists":"","*":"Template:Linear-gradient"},{"ns":10,"exists":"","*":"Template:Drugbankcite"},{"ns":10,"exists":"","*":"Template:Infobox drug/maintenance categories"},{"ns":10,"exists":"","*":"Template:Globalize"},{"ns":10,"exists":"","*":"Template:Ambox"},{"ns":10,"exists":"","*":"Template:Rp"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Cite book"},{"ns":10,"exists":"","*":"Template:ISBN"},{"ns":10,"exists":"","*":"Template:Catalog lookup link"},{"ns":10,"exists":"","*":"Template:Trim"},{"ns":10,"exists":"","*":"Template:Yesno-no"},{"ns":10,"exists":"","*":"Template:Error-small"},{"ns":10,"exists":"","*":"Template:Tl"},{"ns":10,"exists":"","*":"Template:Webarchive"},{"ns":10,"exists":"","*":"Template:Citation"},{"ns":828,"exists":"","*":"Module:Infobox"},{"ns":828,"exists":"","*":"Module:Navbar"},{"ns":828,"exists":"","*":"Module:InfoboxImage"},{"ns":828,"exists":"","*":"Module:List"},{"ns":828,"exists":"","*":"Module:TableTools"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:String"},{"ns":828,"exists":"","*":"Module:TemplatePar"},{"ns":828,"exists":"","*":"Module:ParameterCount"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Message box"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Message box/configuration"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check isxn"},{"ns":828,"exists":"","*":"Module:Error"},{"ns":828,"exists":"","*":"Module:Webarchive"},{"ns":828,"exists":"","*":"Module:Webarchive/data"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":["X_mark.svg","Yes_check.svg","Ambox_globe_content.svg"],"externallinks":["http://www.ajconline.org/article/S0002-9149(14)00975-8/pdf","//doi.org/10.1016/j.amjcard.2014.04.018","//www.ncbi.nlm.nih.gov/pubmed/24846808","http://mitpress.mit.edu/sites/default/files/titles/content/9780262514248_sch_0001.pdf","http://www.bionews.org.uk/page_111448.asp","https://books.google.com/books?id=OVg4AAAAQBAJ","http://www.google.com/patents/US4868179","https://www.ncbi.nlm.nih.gov/pubmed/10496190","http://www.google.com/patents/US6465463","//doi.org/10.1056/NEJM200105033441802","//www.ncbi.nlm.nih.gov/pubmed/11333991","http://www.nejm.org/doi/full/10.1056/NEJMoa042934#t=article","//doi.org/10.1056/NEJMoa042934","//www.ncbi.nlm.nih.gov/pubmed/15533851","http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=BIDIL","http://www.fda.gov/bbs/topics/NEWS/2005/NEW01190.html","http://www.ancecardio.it/it/doc/1160866289744_hfsa_2006_comprehensive_heart_failure_guidelines.pdf","https://web.archive.org/web/20110728080810/http://www.ancecardio.it/it/doc/1160866289744_hfsa_2006_comprehensive_heart_failure_guidelines.pdf","http://www.theheart.org/article/759547/print.do","https://books.google.com/books/about/Fatal_Invention.html?id=_TsaXOpTCSYC","http://www.wnyc.org/shows/radiolab/episodes/2008/11/28/segments/113776","http://www.scientificamerican.com/article.cfm?id=race-based-medicine-a-recipe-for-controversy","http://www.sciam.com/article.cfm?id=race-in-a-bottle","http://www.sciam.com/article.cfm?articleID=194ECC1C-E7F2-99DF-3A3D043D92095CD6","http://www.fdaweb.com/login.php?sa=v&aid=D5106490&cate=&stid=$1$L44.2y1.$rb7LwxobMB2m145JqeU6V","http://www.alternet.org/story/23185/a_bitter_pill_for_black_hearts","http://content.healthaffairs.org/content/25/5/w368.long","http://www.commonchemistry.org/ChemicalDetail.aspx?ref=682335-44-0","https://pubchem.ncbi.nlm.nih.gov/compound/9843669","http://www.chemspider.com/Chemical-Structure.8019384.html","http://www.kegg.jp/entry/D10209","http://www.bidil.com/"],"sections":[{"toclevel":1,"level":"2","line":"Background","number":"1","index":"1","fromtitle":"Isosorbide_dinitrate/hydralazine","byteoffset":2805,"anchor":"Background"},{"toclevel":1,"level":"2","line":"Controversy","number":"2","index":"2","fromtitle":"Isosorbide_dinitrate/hydralazine","byteoffset":7622,"anchor":"Controversy"},{"toclevel":1,"level":"2","line":"See also","number":"3","index":"3","fromtitle":"Isosorbide_dinitrate/hydralazine","byteoffset":10916,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"4","index":"4","fromtitle":"Isosorbide_dinitrate/hydralazine","byteoffset":10974,"anchor":"References"},{"toclevel":1,"level":"2","line":"External links","number":"5","index":"5","fromtitle":"Isosorbide_dinitrate/hydralazine","byteoffset":11004,"anchor":"External_links"}],"parsewarnings":[],"displaytitle":"Isosorbide dinitrate/hydralazine","iwlinks":[],"properties":[{"name":"defaultsort","*":"Isosorbide dinitrate hydralazine"},{"name":"wikibase_item","*":"Q15409422"}]}}